High efficiency cell-specific targeting of cytokine activity

Area of Science:

• Biotechnology
• Immunology
• Molecular Biology

Background:

• Cytokines hold immense therapeutic potential but are limited by systemic toxicity.
• Developing targeted cytokine therapies is crucial for effective medical applications.

Purpose of the Study:

• To engineer immunocytokines with enhanced targeting efficacy.
• To overcome the limitations of systemic toxicity associated with cytokine therapies.

Main Methods:

• Utilized mutants of toxic cytokines with reduced receptor-binding affinities, rendering them inactive.
• Fused these inactive cytokine mutants to nanobodies specific for marker proteins.
• Developed an 'activity-by-targeting' strategy to restore cytokine activity selectively on marker-expressing cells.

Main Results:

• Validated the 'activity-by-targeting' concept using type I interferons and leptin.
• Demonstrated selective in vitro and in vivo targeting of cells with engineered interferons.
• Achieved up to 1,000-fold increased specific activity in targeted cell populations.

Conclusions:

• The novel immunocytokine engineering strategy significantly enhances targeting efficacy.
• This approach overcomes cytokine-induced systemic toxicity, broadening therapeutic potential.
• The 'activity-by-targeting' method offers a promising strategy to revitalize clinical applications of various cytokines.